Nivolumab-induced cholangitis in patients with non-small cell lung cancer: Case series and a review of literature

Immune checkpoint inhibitors (ICIs), including nivolumab, have exhibited substantial benefits in the treatment of several types of cancers. However, treatment with ICIs is often accompanied by immune-related adverse events (irAEs), and a clear understanding of the precise indications and management...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Clin Oncol
Main Authors: Izumi, Hiroki, Kodani, Masahiro, Kurai, Jun, Takeda, Kenichi, Okazaki, Ryota, Yamane, Kohei, Teruya, Yasuhiko, Yamamoto, Akihiro, Sueda, Yuriko, Yanai, Masaaki, Tanaka, Natsumi, Sakamoto, Tomohiro, Yamaguchi, Kosuke, Makino, Haruhiko, Igishi, Tadashi, Yamasaki, Akira
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2019
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6781813/
https://ncbi.nlm.nih.gov/pubmed/31616560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2019.1923
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados